Drug Details

General Information of the Drug (ID: DR9913)
Name
Edrophonium
Synonyms
edrophonium; Edrophonum; Tensilon; EDROPHONIUM ION; 312-48-1; Enlon; Reversol; Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-; Edrophone Chloride; UNII-70FP3JLY7N; N-ethyl-3-hydroxy-N,N-dimethylanilinium; (3-hydroxyphenyl)dimethylethylammonium; 70FP3JLY7N; 3-hydroxy-N,N-dimethyl-N-ethylanilinium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; CHEBI:251408; Ammonium, ethyl(m-hydroxyphenyl)dimethyl-(8CI); ENLON-PLUS; NCGC00015409-02; CAS-116-38-1; ethyl-(3-hydroxyphenyl)-dimethylazanium; Edrophonium cation; Spectrum_000442; Edrophonium Chloride, 3; Prestwick0_000083; Prestwick1_000083; Prestwick2_000083; Prestwick3_000083; Spectrum2_001110; Spectrum4_000736; Spectrum5_001531; Lopac-E-3256; cid_8307; CHEMBL1104; Lopac0_000511; SCHEMBL34790; BSPBio_000006; BSPBio_002386; KBioGR_001032; KBioSS_000922; DivK1c_000809; SPBio_001220; SPBio_001945; BPBio1_000008; GTPL9073; ZINC1341; DTXSID4046943; KBio1_000809; KBio2_000922; KBio2_003490; KBio2_006058; NINDS_000809; BDBM120262; CCG-204602; DB01010; MCULE-5963849469; IDI1_000809; NCGC00015409-01; NCGC00015409-03; NCGC00015409-04; NCGC00015409-05; NCGC00015409-06; NCGC00015409-07; NCGC00015409-08; NCGC00015409-15; NCGC00023975-03; AB00053796; C06976; AB00053796_15; Q3177745
    Click to Show/Hide
Molecular Type
Small molecule
Disease Myasthenia gravis [ICD-11: 8C6Y] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C10H16NO+
PubChem CID
3202
Canonical SMILES
CC[N+](C)(C)C1=CC(=CC=C1)O
InChI
1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
InChIKey
VWLHWLSRQJQWRG-UHFFFAOYSA-O
CAS Number
CAS 312-48-1
ChEBI ID
CHEBI:251408
TTD Drug ID
D0S5LH
DrugBank ID
DB01010
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Reverse the Resistance of This Drug
          Human plasma cholinesterase      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Reversing Drug Resistance     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 The edrophonium-PCHE combination significantly accelerated recovery of mivacurium-induced block compared with that observed with the use of individual antagonists.
Target and Pathway
Target(s) Acetylcholinesterase (AChE)  Molecule Info  [3]
KEGG Pathway Glycerophospholipid metabolism Click to Show/Hide
2 Cholinergic synapse
Panther Pathway Muscarinic acetylcholine receptor 1 and 3 signaling pathway Click to Show/Hide
2 Muscarinic acetylcholine receptor 2 and 4 signaling pathway
3 Nicotinic acetylcholine receptor signaling pathway
Pathwhiz Pathway Phospholipid Biosynthesis Click to Show/Hide
Pathway Interaction Database ATF-2 transcription factor network Click to Show/Hide
WikiPathways Monoamine Transport Click to Show/Hide
2 Biogenic Amine Synthesis
3 Acetylcholine Synthesis
4 Integrated Pancreatic Cancer Pathway
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040131.
Reference 2 Edrophonium and human plasma cholinesterase combination for antagonism of mivacurium-induced neuromuscular block. Br J Anaesth. 1996 Sep;77(3):424-6.
Reference 3 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
 Download Picture         KEGG Link